How to access Braftovi from Oman, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Omani patient diagnosed with BRAF V600E-mutant advanced melanoma, or BRAF V600E-mutant metastatic colorectal cancer in the appropriate setting, may receive a prescription for Braftovi (encorafenib) from their treating medical oncologist. Braftovi is typically used in combination with Mektovi (binimetinib) in melanoma, and in combination with cetuximab in BRAF V600E mutant metastatic colorectal cancer. Braftovi is FDA-approved in the United States. In Oman, Braftovi may not be uniformly stocked across hospital pharmacies, which is why your oncologist may be coordinating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Braftovi in Oman
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Braftovi is an oral selective BRAF kinase inhibitor. Eligibility requires molecular confirmation of a BRAF V600E (or V600K in melanoma) mutation. The manufacturer is Pfizer (following the Array BioPharma acquisition). Dosing is typically 450 mg orally once daily in melanoma (combined with binimetinib) or 300 mg once daily in colorectal cancer (combined with cetuximab). Monitoring includes skin surveillance for new primary cutaneous malignancies, QTc, uveitis symptoms, and liver enzymes. Your oncologist will confirm BRAF status and the combination partner appropriate to your tumour type.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Braftovi legally importable into Oman?
Yes, through Oman Ministry of Health and Prevention (MOHAP) named-patient import framework, with parallel coordination through the Department of Health Abu Dhabi where the administering physician is Abu Dhabi-licensed.
The framework rests on four anchors: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Applications are typically filed by the hospital's importing pharmacy on the physician's behalf.
How the pathway works, step by step
- Consultation with your treating oncologist. The decision to prescribe Braftovi is clinical, based on BRAF status, tumour type, and planned combination partner. Your oncologist documents the rationale.
- Administering facility identification. A Oman tertiary oncology centre with an importing pharmacy files on behalf of the physician.
- MOHAP named-patient application. Your physician or the hospital's importing pharmacy files an application with MOHAP including clinical rationale, combination regimen, patient identifier, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Temperature-controlled shipment. Braftovi is a stable oral capsule; shipments travel with tamper-evident packaging and end-to-end documentation.
- Arrival and dispensing support. Your oncologist remains the treating clinician. Reserve Meds coordinates re-supply ahead of cycle end to avoid treatment gaps.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming BRAF status, tumour type, combination partner, prior therapies, and Braftovi as the indicated treatment
- Verification of their Oman medical licence (MOHAP or DOH Abu Dhabi)
- A current prescription naming the product, strength, and quantity
- Patient identifier (anonymised reference preferred)
- The planned treatment cadence (continuous daily therapy with monthly re-supply)
Reserve Meds provides a physician documentation kit bundling the templates MOHAP reviewers expect to see for oncology oral therapies under named-patient import, including combination regimens.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. Families should separately plan for the cost of the combination partner (binimetinib or cetuximab). Logistics, MOHAP documentation handling, and coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit. Subsequent re-supply cycles are generally faster once the pathway is established.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Braftovi specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for MOHAP review, including combination regimen details.
- Logistics. Temperature-stable shipment and chain-of-custody coordination.
- Dedicated case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.
Frequently asked
Is this legal in Oman? Yes, when executed through the MOHAP named-patient framework with appropriate documentation. See our trust and compliance page.
Can Braftovi and Mektovi be imported together? Yes, the combination is standard of care in BRAF-mutant melanoma. We coordinate both components of the regimen under a single coordinated case.
What about skin surveillance? BRAF inhibitors can cause new cutaneous malignancies; your oncologist will arrange periodic dermatology review. We coordinate supply, not clinical surveillance.
Will private insurance cover this? Cash-pay is the default. Some Oman private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Braftovi coordination in Oman, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Frequently asked questions
How can I get Braftovi in Oman if it is not approved or available there?
Reserve Meds coordinates US-sourced Braftovi for patients in Oman through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Oman and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Braftovi in Oman through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Braftovi. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Oman, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Braftovi in Oman through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Braftovi to a patient in Oman?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Braftovi to your treating physician or hospital pharmacy in Oman, with appropriate handling for the product.
How long does it take, and what does Braftovi in Oman cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Braftovi in Oman?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.